The Pharma Data

OCTOBER 27, 2020

Pharmaceutical-Grade Hand Sanitizer Available for Sale Across Canada. For bulk / commercial sales of DermSafe please contact one of our Canadian distributors or email us directly at info@ovationscience.com. According to Statista.com in late 2019, e-commerce retail trade sales amounted to almost 1.85 Ovation Science Inc.

Sales 52

Sales Production Drug Delivery Development 52

The Pharma Data

MAY 18, 2021

Our Crop Science Division achieved encouraging sales growth in an improved market environment. Sales at Pharmaceuticals were steady, and in the Consumer Health Division we performed better than the competition.” Group sales in the first quarter rose by 2.8 Group sales in the first quarter rose by 2.8 EBIT increased by 23.4

Sales 40

Sales Production Marketing Containment 40

The Pharma Data

JULY 29, 2021

today reports results for the second quarter of 2021, which reflect robust product sales, continued advancement of the pipeline and strong clinical and operational performance across the company. Sales in the same period a year ago were negatively impacted by approximately $350 million of COVID-19-related channel inventory work downs.

Production 52

Production Sales Development Business Development 52

The Pharma Data

AUGUST 17, 2021

An experienced leader in drug development who has led and grown Lilly’s oncology business over the past several years, White will be responsible for Lilly’s launched products and Phase 3 portfolio in pain and neurodegeneration, including the potential launch of donanemab for the treatment of Alzheimer’s disease.

Medicine 52

Medicine Dermatology Production Development 52

The Pharma Data

DECEMBER 23, 2020

While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations.

Vaccination 52

Vaccination Vaccine Development Manufacturing 52

The Pharma Data

NOVEMBER 10, 2020

AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase and is continuously working with business development to find suitable out-licensing solutions with other pharmaceutical companies. This information was brought to you by Cision [link].

Development 40

Development Drugs Protein Research 40

The Pharma Data

NOVEMBER 5, 2020

Collegium will grant Teva a license to market its generic version of Xtampza ER in the United States beginning on or after September 2, 2033 (subject to U.S. Reached a settlement with Teva Pharmaceutical USA, Inc. FDA approval, and customary exceptions).

Production 52

Production Marketing Sales Manufacturing 52

The Pharma Data

NOVEMBER 15, 2020

Prior to Celgene, she held leadership roles in marketing, sales and new business development from 2002 to 2011 at Johnson & Johnson. Most recently, she was a senior executive at Celgene Corporation, where she led corporate strategy from 2012 to 2017. Before that, Ms.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

Pharmaceutical Technology

JULY 23, 2008

It has boosted anti-tumour research by 60% since 2005, at a cost of $1.6bn, in the hope of increasing the share of company sales attributed to cancer drugs from the current level of 5% “There are a lot of patients that are suffering,” said Pfizer chief executive Jeffrey Kindler. So what’s driving the growth?

Drugs 100

Drugs Marketing Sales Development 100

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. Business Development/Other Developments. million of revenue associated with the sale of its rights to Cialis ® in China. Excluding $148.9

Antibody 52

Antibody Sales Development Production 52

The Pharma Data

AUGUST 3, 2021

Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia ® (denosumab), Repatha ® (evolocumab) and our biosimilar products MVASI ® (bevacizumab-awwb) and KANJINTI ® (trastuzumab-anns). Product Sales Performance. Key results include: Total revenues increased 5% to $6.5

Sales 52

Sales Production Antibody Development 52

The Pharma Data

NOVEMBER 5, 2020

net sales increased 11% to $1.32 Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07 “This is evidenced by Dupixent achieving in excess of $1 billion in global net sales this quarter.” Corporate and Business Development Update. TARRYTOWN, N.Y. ,

Sales 40

Sales Production Manufacturing Antibody 40

pharmaphorum

OCTOBER 1, 2021

It has made Oxford Nanopore’s chief executive and cofounder Gordon Sanghera an on-paper fortune of £63 million, while another cofounder – chief business development officer Spike Willcocks – is now worth £30 million. Chief technology officer Clive Brown is also sitting on a £10 million stake.

Marketing 52

Marketing Genome Genomics Business Development 52

The Pharma Data

AUGUST 6, 2020

NEW YORK–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2020, which reflect strong product sales, continued advancement of the pipeline and robust operating performance. announced that the companies submitted the Biologics License Application (BLA) to the U.S.

Production 52

Production Branding Marketing Containment 52

The Pharma Data

JANUARY 27, 2021

Finalized the technical development of modia , a digital therapy for opioid use disorder, for which Orexo owns the exclusive global rights. Entered an exclusive license and supply agreement with Accord Healthcare for ZUBSOLV® covering 29 European countries. Important events after the period.

Production 40

Production Marketing Sales Development 40

The Pharma Data

OCTOBER 26, 2020

Sales. billion related to certain license and collaboration agreements, and certain other items. The FDA has granted V181, the company’s investigational dengue vaccine in Phase 1 development, Fast Track designation. Business Developments. 2019.

Sales 40

Sales Vaccination Vaccine Production 40

XTalks

AUGUST 2, 2023

Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

MAY 4, 2021

Following the completion of the spin-off of the Upjohn Business (4) in the fourth quarter of 2020, Pfizer now operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide. previously $59.4 21% to 22%.

Vaccination 40

Vaccination Vaccine Production Sales 40